Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Barbera

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
Journal of Medicinal Chemistry|January 14, 2000
Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3)D G Batt, J J Petraitis, G C Houghton, et al.
The European Respiratory Journal|September 15, 2009
Guidelines for the diagnosis and treatment of pulmonary hypertension, , , et al.
Bioorganic & Medicinal Chemistry Letters|February 19, 2013
Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitorsXiaojun Zhang, Peter W Glunz, Wen Jiang, et al.
Bioorganic & Medicinal Chemistry Letters|January 17, 2015
Pyridine and pyridinone-based factor XIa inhibitorsJames R Corte, Tianan Fang, Jon J Hangeland, et al.
The Oncologist|April 2, 2016
Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma PatientsGiovanni Brandi, Marzia Deserti, Francesco Vasuri, et al.
The Oncologist|November 4, 2016
In ReplyGiovanni Brandi, Marzia Deserti, Francesco Vasuri, et al.
Scientific Reports|October 29, 2021
Mapping of population disparities in the cholangiocarcinoma urinary metabolomeMunirah Alsaleh, Zoe Leftley, Thomas O'Connor, et al.
Journal of Medicinal Chemistry|January 11, 2014
Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitorsMimi L Quan, Pancras C Wong, Cailan Wang, et al.
Journal of Clinical and Experimental Hepatology|February 7, 2020
Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom CohortMunirah Alsaleh, Zoe Leftley, Thomas A Barbera, et al.
British Journal of Cancer|April 10, 2014
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancerL Fornaro, S Cereda, G Aprile, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Journal of Medicinal Chemistry|January 14, 2000
Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3)D G Batt, J J Petraitis, G C Houghton, et al.
The European Respiratory Journal|September 15, 2009
Guidelines for the diagnosis and treatment of pulmonary hypertension, , , et al.
Bioorganic & Medicinal Chemistry Letters|February 19, 2013
Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitorsXiaojun Zhang, Peter W Glunz, Wen Jiang, et al.
Bioorganic & Medicinal Chemistry Letters|January 17, 2015
Pyridine and pyridinone-based factor XIa inhibitorsJames R Corte, Tianan Fang, Jon J Hangeland, et al.
The Oncologist|April 2, 2016
Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma PatientsGiovanni Brandi, Marzia Deserti, Francesco Vasuri, et al.
The Oncologist|November 4, 2016
In ReplyGiovanni Brandi, Marzia Deserti, Francesco Vasuri, et al.
Scientific Reports|October 29, 2021
Mapping of population disparities in the cholangiocarcinoma urinary metabolomeMunirah Alsaleh, Zoe Leftley, Thomas O'Connor, et al.
Journal of Medicinal Chemistry|January 11, 2014
Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitorsMimi L Quan, Pancras C Wong, Cailan Wang, et al.
Journal of Clinical and Experimental Hepatology|February 7, 2020
Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom CohortMunirah Alsaleh, Zoe Leftley, Thomas A Barbera, et al.
British Journal of Cancer|April 10, 2014
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancerL Fornaro, S Cereda, G Aprile, et al.
Pageof 12